Skanska (STO:SKAB) has signed a contract with Merck (NYSE:MRK), known outside of the United States and Canada as MSD, to complete the renovation of a research and development laboratory at Merck's facility in Kenilworth, New Jersey.
The contract value for Skanska is USD 80 M, about SEK 512 M, which will be included in order bookings for Skanska USA Building in the third quarter.
The project includes the extensive renovation of more than 23,000 square meters of chemistry and biology laboratories. Work on the project begins in November 2011, and is scheduled to be completed in the Spring 2013.
Skanska USA is one of the leading development and construction companies in the country, consisting of four business units: Skanska USA Building, which specializes in building construction; Skanska USA Civil, specialized in civil infrastructure; Skanska Infrastructure Development, which develops public-private partnerships; and Skanska Commercial Development, which develops commercial development projects in select U.S. markets. Headquartered in New York, Skanska USA has approximately 7,400 employees and its 2010 revenues were SEK 34.3 billion.
This and previous releases can also be found at www.skanska.com (http://www.skanska.com/)
Skanska AB may be required to disclose the information provided herein pursuant to the Securities Markets Act.
Skanska is one of the world’s leading project development and construction groups with expertise in construction, development of commercial and residential projects and public-private partnerships. Based on its global green experience, Skanska aims to be the clients' first choice for Green solutions. The Group currently has 52,000 employees in selected home markets in Europe, in the US and Latin America. Headquartered in Stockholm, Sweden and listed on the Stockholm Stock Exchange, Skanska's sales in 2010 totaled SEK 122 billion.